Clinical Biomarker of Paclitaxel-induced Peripheral Neuropathy
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
Investigation of which patients treated with paclitaxel have an increased risk of developing peripheral neuropathy.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
View:
• Age \> 18 years
• Willing to give informed consent
• Scheduled to receive neo-adjuvant or adjuvant paclitaxel treatment
• Able to speak and understand Danish
• Diagnosed with breast cancer
• Paclitaxel naïve patients
Locations
Other Locations
Denmark
Odense University Hospital
RECRUITING
Odense
University Hospital of Southern Denmark, Sønderborg
RECRUITING
Sønderborg
University Hospital of Southern Denmark, Vejle
RECRUITING
Vejle
Contact Information
Primary
Ditte Bork Iversen, MSc Pharm, PhD
dbiversen@health.sdu.dk
+45 65 50 23 52
Backup
Tore B. Stage, Prof
tstage@health.sdu.dk
+45 65 50 36 78
Time Frame
Start Date: 2024-10-10
Estimated Completion Date: 2027-09
Participants
Target number of participants: 188
Treatments
Breastcancer patients
A total of 188 patients diagnosed with breast cancer who are scheduled for paclitaxel treatment, either as adjuvant or neo-adjuvant treatment, will be recruited across three trial sites.
Related Therapeutic Areas
Sponsors
Collaborators: Odense University Hospital, Sygehus Lillebaelt, Sonderborg Hospital
Leads: University of Southern Denmark